欢迎访问《现代生物医学进展》编辑部！

目的：探讨布地奈德联合孟鲁司特钠对支气管哮喘患儿细胞因子、免疫功能影响。方法：选自我院于2014 年9 月~2016 年3 月期间收治的支气管哮喘患儿96 例，依据随机数字表法随机分为观察组与对照组，每组48 例。对照组给予孟鲁司特钠治疗，观察组在对照组基础上结合布地奈德治疗。两组疗程均为4 周。观察并比较两组的临床疗效、以及治疗前后患者血清细胞因子水平、免疫功能及肺功能的变化情况。结果：观察组治疗总有效率（95.83 %）高于对照组（79.17 %）（P<0.05）；观察组血清IL-5 含量治疗后低于对照组，而IL-12 含量高于对照组（P<0.05）；观察组血清IgE 含量治疗后低于对照组，而IgA、IgM含量高于对照组（P<0. 05）；观察组FEV1 和FVC 治疗后高于对照组（P<0.05）；两组均未见明显不良反应。结论：布地奈德联合孟鲁司特钠治疗支气管哮喘患儿疗效显著，且作用可能与改善细胞因子、免疫功能及肺功能有关。

英文摘要:

Objective:To investigate the effect of budesonide combined with montelukast on cytokines, immune function in children with asthma.Methods:96 cases of children with asthma were randomly divided into two groups with 48 cases each group. The children in control group were received montelukast treatment, and the children in observation group were treated with budesonide based on the control group. The treatment lasted 4 weeks. The level of cytokines, immune function and lung function levels were observed and compared, and the clinical efficacy and the incidence of adverse reactions were detected.Results:The total effective rate in observation group was 95.83 %, obviously higher than 79.17 % of control group (P<0.05).Compared with control group after treatment, the serum IL-5 content was lower, and the IL-12 level was higher in observation group (P<0.05). Compared with control group after treatment, the serumIgE levels was lower, while the IgA, IgMlevel was higher in observation group (P<0.05). The FEV1 and FVC level was higher in the observation group after treatment compared with control group (P<0.05). The two groups had no significant adverse reactions.Conclusion:Budesonide combined with montelukast sodium has good clinical effect in the treatment of bronchial asthma in children, which may be related to improvement of cytokines, immune function and pulmonary function.

查看全文查看/发表评论下载PDF阅读器

关闭